Actionable news
All posts from Actionable news
Actionable news in NVS: NOVARTIS AG,

Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer

CHANTILLY, Va., May 4, 2016 /PRNewswire/ -- Notal Vision, Inc., a privately-held ophthalmic company that introduced the first home-based monitoring system, ForeseeHome®, for patients with age-related macular degeneration (AMD), announced today that Quinton Oswald has assumed the role of Chief Executive Officer. Co-founder, Barak Azmon, MD, will continue to serve on Notal's board of directors.

Quinton Oswald brings over 13 years of ophthalmic experience to Notal. He was most recently the CEO of Neurotech Pharmaceuticals and, prior to that, CEO of SARcode Bioscience where he was instrumental in the clinical development of lifitegrast ophthalmic solution for the treatment of dry eye disease and its subsequent sale to Shire, PLC. Previously, he was Vice President & Business Unit Head for Genentech's Tissue Growth and Repair Business, which generated over $2.1 billion in annual sales. During his tenure at Genentech, Mr. Oswald also oversaw the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

"We are very excited and honored to welcome Quinton Oswald to Notal as the new Chief Executive Officer, and believe that his unique leadership skills and expertise in the retinal space make him an ideal addition to the team," stated Guy Katsav, Chairman of Notal Vision. "Quinton's ophthalmic experience ranges from leading the launch of Lucentis® at Genentech to raising over $40 million at SARcode Bioscience, and successfully negotiating the sale of lifitegrast, a potential blockbuster dry eye...